Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era

Related Experiment Video

Updated: Apr 22, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

13.9K

Christopher R Flowers1, Jonathon B Cohen, Mohammad K Khan

  • 1Division of Bone Marrow and Stem Cell Transplantation/Department of Hematology/Oncology.

Leukemia & Lymphoma
|October 16, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

7.4K

Related Experiment Videos

Last Updated: Apr 22, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

13.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

7.4K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

387
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
387

Articles linked to this work by shared authors, journal, and citation graph.

Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma.

Blood cancer discovery·2026

Microbial valerate is associated with CAR T dysbiosis and its supplementation enhances CAR T function in B-cell lymphoma.

bioRxiv : the preprint server for biology·2026

Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.

Blood cancer journal·2026

Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.

Blood neoplasia·2026

Comorbidity Burden and Prognosis in Patients Aged 80+ Years With Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026

Developing Effective, Evidence-Based Training for Cancer Team Science Leadership for National Impact.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Leukemia & lymphoma·2026

Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Leukemia & lymphoma·2026

Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.

Leukemia & lymphoma·2026

Zanubrutinib with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory non-germinal center B-cell lymphoma.

Leukemia & lymphoma·2026

Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.

Leukemia & lymphoma·2026

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us